<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383680</url>
  </required_header>
  <id_info>
    <org_study_id>CS_2014_01</org_study_id>
    <nct_id>NCT02383680</nct_id>
  </id_info>
  <brief_title>Yellow Fever Vaccination Under Low Dose Methotrexate Therapy</brief_title>
  <acronym>MTX_YF</acronym>
  <official_title>Yellow Fever Vaccination Under Low Dose Methotrexate Therapy - a Multi-Center Prospective Observational Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Aarau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Travelers (n = 30, 15 taking low-dose methotrexate (MTX), 15 healthy controls (HC), seeking
      travel advice in one of the following Swiss Travel Centers (Aarau, Basel, Bern, Geneva,
      Lausanne, Zurich) and who have an indication for yellow fever (YF) vaccination according to
      the Swiss Federal Office of Public Health's vaccination recommendations are invited to
      participate in this study. After signing the consent form (i) YF viremia and (ii) anti-YF
      antibody production in patients taking low-dose MTX and HC will be compared after YF
      vaccination. It will be analyzed whether the percentage of people with protective antibodies
      differs between the two groups and (iii) vaccine side effects will be compared between the
      groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in the form of a multi-center open-label prospective
      observational controlled pilot study. 15 patients under low dose methotrexate treatment and
      15 healthy controls with an indication for yellow fever vaccination will be included. The
      study duration will be 28 days for each subject and will consist of 6 clinical visits on days
      0, 3, 7, 10, 14 and 28.

      YF antibodies will be measured on days 0, 7, 10, 14 and 28; viremia will be measured on days
      3, 7, 10, 14 and 28.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative viremia in blood in travelers under low dose methotrexate (≤20mg/week) and healthy travelers</measure>
    <time_frame>days 3, 7, 10 and 14 and 28</time_frame>
    <description>Serum samples will be collected for PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative yellow fever specific neutralizing antibodies in blood of travelers under low dose methotrexate therapy (≤20mg/week) and healthy travelers</measure>
    <time_frame>days 0, 7, 10, 14 and 28</time_frame>
    <description>Serum samples will be collected for measurement of neutralizing antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the percentage of travelers with an antibody level of &gt;0.7 LNI (&gt;0.5 IU/ml) in both groups</measure>
    <time_frame>days 0, 7, 10, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety by determining the severity and quantity of adverse vaccine reactions such as local and systemic reactions in both study groups</measure>
    <time_frame>Throughout day 28 after vaccination</time_frame>
    <description>Local and systemic vaccine reactions will be collected in a diray card filled out by the participant</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rheumatic</condition>
  <condition>Dermatologic Disorders</condition>
  <arm_group>
    <arm_group_label>Patients under low dose methotrexate therapy</arm_group_label>
    <description>Patients with various underlying conditions (e.g. rheumatic diseases, dermatologic diseases) who have an indication for yellow fever vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy travelers who have an indication for yellow fever vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Yellow Fever Vaccination</intervention_name>
    <description>The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.</description>
    <arm_group_label>Patients under low dose methotrexate therapy</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Travelers seeking pre-travel advice with an indication for yellow fever vaccination will be
        addressed in 6 Swiss Travel Clinics of the Cantonal Hospital Aarau, the University Hospital
        in Bern, the University of Zurich, teh University Hospital of Geneva and the Swiss Tropical
        and Public Health Instutute in Basel
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent as documented by signature

          -  Indication for yellow fever vaccination according to Swiss FOPH recommendations

          -  Individuals under low dose MTX (≤20mg/week) therapy or healthy individuals

          -  Male and Female travelers ≥18 years to &lt;60 years of age

        Exclusion Criteria:

          -  Contraindications on ethical grounds

          -  Women who are pregnant or breast feeding

          -  Contraindication against yellow fever vaccination (e.g. hypersensitivity against
             vaccine ingredient)

          -  Current treatment with other immunosuppressive agent apart from low dose methotrexate

          -  Alemtuzumab or rituximab in the last year

          -  TNF-blocking therapy in past three months

          -  Immunocompromising condition in healthy control

          -  Other immunocompromising condition than MTX treatment itself and the underlying
             disease in patients under MTX

          -  Previous yellow fever vaccination

          -  No indication for yellow fever vaccination according to Swiss travel vaccination
             recommendations

          -  Known or suspected non-compliance, drug or alcohol abuse

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Hatz, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich, Epidemiolgy, Biostatistics and Prevention Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silja Bühler, MD MSc</last_name>
    <phone>+41 44634</phone>
    <phone_ext>4631</phone_ext>
    <email>silja.buehler@ifspm.uzh.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Hatz, Prof MD</last_name>
    <phone>+41 44634</phone>
    <phone_ext>4608</phone_ext>
    <email>christoph.hatz@unibas.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Aargau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Fux, PD MD</last_name>
      <phone>+41 62 838 68 20</phone>
      <email>christoph.fux@ksa.ch</email>
    </contact>
    <contact_backup>
      <last_name>Constanze Spelters, Study Nurse</last_name>
      <phone>+41 62 838 68 20</phone>
      <email>constanze.spelters@ksa.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Swiss Tropical and Public Health Institute</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Kling, MD</last_name>
      <phone>+41 61284</phone>
      <phone_ext>8119</phone_ext>
      <email>kerstin.kling@unibas.ch</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Hatz, Prof MD</last_name>
      <phone>+ 41 61284</phone>
      <phone_ext>8255</phone_ext>
      <email>christoph.hatz@unibas.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Infektiologie Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hansjakob Furrer, Prof MD</last_name>
      <phone>+41 31 632 27 45</phone>
      <email>Hansjakob.Furrer@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Cornelia Staehelin, MD</last_name>
      <phone>+41 31 632 27 45</phone>
      <email>cornelia.staehelin@insel.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Médecine Tropicale et Humanitaire Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles Eperon, MD</last_name>
      <phone>+41 (0)22 372 96 15</phone>
      <email>Gilles.Eperon@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Francois Chappuis, Prof MD</last_name>
      <phone>+41 (0)22 372 96 15</phone>
      <email>francois.chappuis@hcuge.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>PMU | Policlinique médicale universitaire CHUV | Service des maladies infectieuses, Département de médecine</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Blaise Genton, Prof MD</last_name>
      <phone>+41 21 314 67 68</phone>
      <email>Blaise.Genton@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Zurich, Epidemiology, Biostatistics and Prevention Institute</name>
      <address>
        <city>Zurich</city>
        <zip>8001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silja Bühler, MD MSc</last_name>
      <phone>+41 44634</phone>
      <phone_ext>4631</phone_ext>
      <email>silja.buehler@ifspm.uzh.ch</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Schmid, MD</last_name>
      <phone>+41 44634</phone>
      <phone_ext>4608</phone_ext>
      <email>sabine.schmid@ifspm.uzh.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methotrexate therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yellow Fever</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

